Study procedures
throat
BLOOD, SARS-COV-2 INFECTION
All participants received a single dose of 0.5 mL of either SII-NVX-CoV2373 or control vaccine on day 1 as per randomization. Blood samples were collected at baseline (day 1), days 29 (+7), 91 (+7) and 181 (+14) for immunogenicity assessments including anti-S IgG and nAbs. Additionally, a blood sample was collected in a subset for assessment of cell mediated immune (CMI) responses at baseline, days 29 and 181.A nasopharyngeal/nasal and/or throat swab was collected for RT-PCR test for detection of SARS-CoV-2 infection at baseline before vaccination on day 1 and also, if participants presented with symptoms of suspected COVID-19 or had a history of contact with a confirmed COVID-19 case at any time during the study.Physical examination and vital sign evaluations were performed and medical history and prior/concomitant medications were recorded on days 1, 29, 91 and 181. Vital signs were also measured at 30 min post-vaccination.